Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia [0.03%]
纵向细胞因子谱分析鉴定出GRO-α和EGF是原发性血小板增多症病情进展的潜在生物标志物
Nina F Øbro,Jacob Grinfeld,Miriam Belmonte et al.
Nina F Øbro et al.
Myeloproliferative neoplasms (MPNs) are characterized by deregulation of mature blood cell production and increased risk of myelofibrosis (MF) and leukemic transformation. Numerous driver mutations have been identified but substantial disea...
Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice [0.03%]
开发多发性骨髓瘤患者的以患者为中心的结果评估集用于临床实践
Simone Oerlemans,M Christine Bennink,Mark David Levin et al.
Simone Oerlemans et al.
Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis [0.03%]
JAK2V617F突变患者内皮colony-forming细胞在血管形成和门静脉血栓中的作用缺失现象研究
Alexandre Guy,Anicee Danaee,Koralia Paschalaki et al.
Alexandre Guy et al.
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials [0.03%]
伊布替尼单药治疗临床试验内外华氏巨球蛋白血症患者的疗效及生存预后分析
Jorge J Castillo,Joshua N Gustine,Kirsten Meid et al.
Jorge J Castillo et al.
Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether ther...
Francesca Vinchi,Saskia Hell,Uwe Platzbecker
Francesca Vinchi
Many patients with MDS are prone to develop systemic and tissue iron overload in part as a consequence of disease-immanent ineffective erythropoiesis. However, chronic red blood cell transfusions, which are part of the supportive care regim...
Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis [0.03%]
一名原发性骨髓纤维化患者在JAK2抑制剂治疗过程中快速出现慢性淋巴细胞性白血病
Nikolaos Sousos,Gemma Buck,Alba Rodriguez-Meira et al.
Nikolaos Sousos et al.
Supplemental Digital Content is available in the text
Nicholas Chiorazzi,Freda K Stevenson
Nicholas Chiorazzi
The division of CLL into 2 broad subsets with highly significant differences in clinical behavior was reported in 2 landmark papers in Blood in 1999.1,2 The simple analysis of the mutational status of the IGV regions provided both a prognos...
Mutant Calreticulin in the Myeloproliferative Neoplasms [0.03%]
我的eloproliferative肿瘤中的突变calreticulin蛋白质
Daniel Prins,Carlos González Arias,Thorsten Klampfl et al.
Daniel Prins et al.
Mutations in the gene for calreticulin (CALR) were identified in the myeloproliferative neoplasms (MPNs) essential thrombocythaemia (ET) and primary myelofibrosis (MF) in 2013; in combination with previously described mutations in JAK2 and ...
Kai Hübel,Michele Ghielmini,Marco Ladetto et al.
Kai Hübel et al.
The overall prognosis of patients with follicular lymphoma has substantially improved over the last decades with a 10-year overall survival of around 80% for the majority of patients. However, for most patients follicular lymphoma it is sti...
EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in Hematology [0.03%]
EHA科学工作组：连接科学和传播血液学知识
Pieter Sonneveld
Pieter Sonneveld